The Union for Affordable Cancer Treatment is asking Sherry Lansing, the former Paramount CEO and current member of the Board of Regents of the University of California, to stop the Regents’ efforts to obtain a patent on the prostate cancer drug enzalutamide (brand name Xtandi) in India. On May 24th, 2017, UACT was joined by 56 civil society organizations and academic experts in sending a letter to Janet Napolitano, President of the University of California system, and the Board of Regents of the University of California, requesting that they withdraw their efforts to obtain a patent on enzalutamide in India. Neither Napolitano’s office nor theRead More →

Time for cancer patients to come before corporate profits by Manon Ress, co founder and acting director of UACT First posted by MOHGA KAMAL-YANNI ON JUN 15TH, 2017 IN ACCESS TO MEDICINES, INEQUALITY, NON COMMUNICABLE DISEASES, UNIVERSAL HEALTH COVERAGE http://www.globalhealthcheck.org/?p=1973 On 26th Of May, the World Health Assembly adopted the long debated Resolution on Cancer Prevention and Control. This is an important step towards supporting countries to address this disease in order to achieve Universal Health Coverage (UHC). Cancers are a leading cause of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths in 2012, 70% of which occurredRead More →

On May 31, 2017, World Health Assembly adopted a new resolution on the prevention and control of cancer.   UACT earlier wrote about the negotiations on the resolution here and here.  IP-Watch published a story about the resolution here.  A not quite final version of the text is here. The following are statements from four members of UACT:   Dr. Manon Ress, Founder and Acting Director, Union for Affordable Cancer Treatment (UACT) UACT was among 29 civil society organizations and 33 health professionals, activists, and economists — including Nobel Prize laureate Joseph Stiglitz — asking delegates to WHA to support a feasibility study on theRead More →

On Wednesday, 24 May 2017, UACT participated in Knowledge Ecology International (KEI), Oxfam and Stichting Health Action International (HAI) WHA side event on addressing access barriers and affordability challenges for cancer medicines. This event focused on policy options to address the access barriers and affordability challenges for cancer medicines, in conjunction with the Assembly’s consideration of agenda item 15.6 – Cancer prevention and control in the context of an integrated approach. In 2012, cancer was the 2nd leading cause of death in the world (8.2 million); cancer cases are projected to increase from 14.1 million in 2012 to 21.6 million in 2030. Panelists will addressRead More →

On May 24, 2017, the Union for Affordable Cancer treatment and 56 civil society organizations and academic experts called Janet Napolitano, the President of the University of California, and the Board of Regents, “withdraw your efforts to obtain a patent on the prostate cancer drug enzalutamide (brand name Xtandi) in India.”  A PDF copy of the letter is available here: UACT-U-Cal-Xtandi-Patent-India-2017May24 The text of the letter is as follows: Janet Napolitano, University of California, Office of the President, 1111 Franklin Street, Oakland, CA 94607 via email: president@ucop.edu Board of Regents of the University of California, Office of the Secretary and Chief of Staff to the Regents, 1111 Franklin St., 12th floor, Oakland, CA 94607, via email:Read More →